Moreover, irisin is considered a potential therapeutic agent against obesity, which is a well-known risk factor for many malignancies, including cancers of the esophagus, colon, and rectum; however, its role in GI tract cancers has not been fully explained [82,83,84,85,86]. This evidence concerns the gene FNDC5 and obesity due to melanocortin 4 receptor deficiency.